Literature DB >> 6769749

The gastrointestinal manifestations of scleroderma: pathogenesis and management.

S Cohen.   

Abstract

This case exemplifies the severe gastrointestinal manifestations of scleroderma. Esophageal, gastric, small intestinal, and colonic motility disorders were present. The patient was unable to survive on oral feedings or tube feedings. He was clinically resistant to the pharmacologic stimulation of gastrointestinal motility. After considerable discussion the patient was begun on intravenous hyperalimentation to be performed at home. Approximately 1 hr later, he has done remarkably well. He has maintained his weight and has had only one brief hospitalized for a sepsis most likely related to the intravenous feedings. He is still unable to take oral feedings. Other organs have remained clinically uninvolved, and the skin and joint disease have remained stable. It is our feeling that intravenous home alimentation has provided a useful adjunct to management in this patient with severe gastrointestinal involvement of scleroderma. It is hoped that the newer therapeutic modalities described by Dr. Jimenez may be effective in patients with this disease who can now be nourished parenterally.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6769749

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  40 in total

1.  [Acrocyanosis: crucial symptom in a case of chronic diarrhea and weight loss].

Authors:  N Hackelsberger; T Schmidt; A Stein; W Schepp
Journal:  Internist (Berl)       Date:  2003-11       Impact factor: 0.743

2.  Dietary intake and nutritional status in patients with systemic sclerosis.

Authors:  A C Lundberg; A Akesson; B Akesson
Journal:  Ann Rheum Dis       Date:  1992-10       Impact factor: 19.103

3.  A case of pseudoobstruction of the intestine associated with scleroderma dramatically responding to antibiotics.

Authors:  Hiroaki Itou; Masahiro Iizuka; Kenichi Shindo; Shiho Konno; Sumio Watanabe
Journal:  J Gastroenterol       Date:  2006-07       Impact factor: 7.527

4.  Effects of famotidine on upper gastrointestinal motility in patients with progressive systemic sclerosis.

Authors:  T Horikoshi; T Sekiguchi; M Kusano; T Matsuzaki
Journal:  Gastroenterol Jpn       Date:  1991-04

5.  Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis patients.

Authors:  T A McNearney; H S Sallam; S E Hunnicutt; D Doshi; D E Wollaston; M D Mayes; J D Z Chen
Journal:  Neurogastroenterol Motil       Date:  2009-06-30       Impact factor: 3.598

6.  Air in the oesophagus: a sign of oesophageal involvement in systemic sclerosis.

Authors:  A Olivé; S Juncosa; G Evison; P J Maddison
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

7.  Impedance planimetric characterization of esophagus in systemic sclerosis patients with severe involvement of esophagus.

Authors:  G E Villadsen; J H Storkholm; L Hendel; H Vilstrup; H Gregersen
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

8.  Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells.

Authors:  Jagmohan Singh; Vaibhav Mehendiratta; Francesco Del Galdo; Sergio A Jimenez; Sidney Cohen; Anthony J DiMarino; Satish Rattan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-09-24       Impact factor: 4.052

9.  Elevated ANA titers in patients with severely abnormal gastrointestinal motility.

Authors:  E E Soffer; M P Strottmann; S Anuras
Journal:  Dig Dis Sci       Date:  1984-08       Impact factor: 3.199

10.  Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction.

Authors:  G N Verne; E Y Eaker; E Hardy; C A Sninsky
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.